Development and validation of the Arizona Cognitive Test Battery for Down syndrome

Jamie O Edgin, Gina M. Mason, Melissa J. Allman, George T. Capone, Iser DeLeon, Cheryl Maslen, Roger H. Reeves, Stephanie L. Sherman, Lynn Nadel

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Neurocognitive assessment in individuals with intellectual disabilities requires a well-validated test battery. To meet this need, the Arizona Cognitive Test Battery (ACTB) has been developed specifically to assess the cognitive phenotype in Down syndrome (DS). The ACTB includes neuropsychological assessments chosen to 1) assess a range of skills, 2) be non-verbal so as to not confound the neuropsychological assessment with language demands, 3) have distributional properties appropriate for research studies to identify genetic modifiers of variation, 4) show sensitivity to within and between sample differences, 5) have specific correlates with brain function, and 6) be applicable to a wide age range and across contexts. The ACTB includes tests of general cognitive ability and prefrontal, hippocampal and cerebellar function. These tasks were drawn from the Cambridge Neuropsychological Testing Automated Battery (CANTAB) and other established paradigms. Alongside the cognitive testing battery we administered benchmark and parent-report assessments of cognition and behavior. Individuals with DS (n=74, ages 7-38 years) and mental age (MA) matched controls (n=50, ages 3-8 years) were tested across 3 sites. A subsample of these groups were used for between-group comparisons, including 55 individuals with DS and 36 mental age matched controls. The ACTB allows for low floor performance levels and participant loss. Floor effects were greater in younger children. Individuals with DS were impaired on a number ACTB tests in comparison to a MA-matched sample, with some areas of spared ability, particularly on tests requiring extensive motor coordination. Battery measures correlated with parent report of behavior and development. The ACTB provided consistent results across contexts, including home vs. lab visits, cross-site, and among individuals with a wide range of socio-economic backgrounds and differences in ethnicity. The ACTB will be useful in a range of outcome studies, including clinical trials and the identification of important genetic components of cognitive disability.

Original languageEnglish (US)
Pages (from-to)149-164
Number of pages16
JournalJournal of Neurodevelopmental Disorders
Volume2
Issue number3
DOIs
StatePublished - 2010

Fingerprint

Down Syndrome
Aptitude
Benchmarking
Intellectual Disability
Cognition
Language
Economics
Outcome Assessment (Health Care)
Clinical Trials
Phenotype
Brain
Research

Keywords

  • Assessment
  • Clinical trials
  • Down syndrome
  • Genetics
  • Intellectual disabilities
  • Neuropsychology

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Cognitive Neuroscience
  • Pediatrics, Perinatology, and Child Health

Cite this

Development and validation of the Arizona Cognitive Test Battery for Down syndrome. / Edgin, Jamie O; Mason, Gina M.; Allman, Melissa J.; Capone, George T.; DeLeon, Iser; Maslen, Cheryl; Reeves, Roger H.; Sherman, Stephanie L.; Nadel, Lynn.

In: Journal of Neurodevelopmental Disorders, Vol. 2, No. 3, 2010, p. 149-164.

Research output: Contribution to journalArticle

Edgin, JO, Mason, GM, Allman, MJ, Capone, GT, DeLeon, I, Maslen, C, Reeves, RH, Sherman, SL & Nadel, L 2010, 'Development and validation of the Arizona Cognitive Test Battery for Down syndrome', Journal of Neurodevelopmental Disorders, vol. 2, no. 3, pp. 149-164. https://doi.org/10.1007/s11689-010-9054-3
Edgin, Jamie O ; Mason, Gina M. ; Allman, Melissa J. ; Capone, George T. ; DeLeon, Iser ; Maslen, Cheryl ; Reeves, Roger H. ; Sherman, Stephanie L. ; Nadel, Lynn. / Development and validation of the Arizona Cognitive Test Battery for Down syndrome. In: Journal of Neurodevelopmental Disorders. 2010 ; Vol. 2, No. 3. pp. 149-164.
@article{19fce222622e4f499ca53980921ac997,
title = "Development and validation of the Arizona Cognitive Test Battery for Down syndrome",
abstract = "Neurocognitive assessment in individuals with intellectual disabilities requires a well-validated test battery. To meet this need, the Arizona Cognitive Test Battery (ACTB) has been developed specifically to assess the cognitive phenotype in Down syndrome (DS). The ACTB includes neuropsychological assessments chosen to 1) assess a range of skills, 2) be non-verbal so as to not confound the neuropsychological assessment with language demands, 3) have distributional properties appropriate for research studies to identify genetic modifiers of variation, 4) show sensitivity to within and between sample differences, 5) have specific correlates with brain function, and 6) be applicable to a wide age range and across contexts. The ACTB includes tests of general cognitive ability and prefrontal, hippocampal and cerebellar function. These tasks were drawn from the Cambridge Neuropsychological Testing Automated Battery (CANTAB) and other established paradigms. Alongside the cognitive testing battery we administered benchmark and parent-report assessments of cognition and behavior. Individuals with DS (n=74, ages 7-38 years) and mental age (MA) matched controls (n=50, ages 3-8 years) were tested across 3 sites. A subsample of these groups were used for between-group comparisons, including 55 individuals with DS and 36 mental age matched controls. The ACTB allows for low floor performance levels and participant loss. Floor effects were greater in younger children. Individuals with DS were impaired on a number ACTB tests in comparison to a MA-matched sample, with some areas of spared ability, particularly on tests requiring extensive motor coordination. Battery measures correlated with parent report of behavior and development. The ACTB provided consistent results across contexts, including home vs. lab visits, cross-site, and among individuals with a wide range of socio-economic backgrounds and differences in ethnicity. The ACTB will be useful in a range of outcome studies, including clinical trials and the identification of important genetic components of cognitive disability.",
keywords = "Assessment, Clinical trials, Down syndrome, Genetics, Intellectual disabilities, Neuropsychology",
author = "Edgin, {Jamie O} and Mason, {Gina M.} and Allman, {Melissa J.} and Capone, {George T.} and Iser DeLeon and Cheryl Maslen and Reeves, {Roger H.} and Sherman, {Stephanie L.} and Lynn Nadel",
year = "2010",
doi = "10.1007/s11689-010-9054-3",
language = "English (US)",
volume = "2",
pages = "149--164",
journal = "Journal of Neurodevelopmental Disorders",
issn = "1866-1947",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Development and validation of the Arizona Cognitive Test Battery for Down syndrome

AU - Edgin, Jamie O

AU - Mason, Gina M.

AU - Allman, Melissa J.

AU - Capone, George T.

AU - DeLeon, Iser

AU - Maslen, Cheryl

AU - Reeves, Roger H.

AU - Sherman, Stephanie L.

AU - Nadel, Lynn

PY - 2010

Y1 - 2010

N2 - Neurocognitive assessment in individuals with intellectual disabilities requires a well-validated test battery. To meet this need, the Arizona Cognitive Test Battery (ACTB) has been developed specifically to assess the cognitive phenotype in Down syndrome (DS). The ACTB includes neuropsychological assessments chosen to 1) assess a range of skills, 2) be non-verbal so as to not confound the neuropsychological assessment with language demands, 3) have distributional properties appropriate for research studies to identify genetic modifiers of variation, 4) show sensitivity to within and between sample differences, 5) have specific correlates with brain function, and 6) be applicable to a wide age range and across contexts. The ACTB includes tests of general cognitive ability and prefrontal, hippocampal and cerebellar function. These tasks were drawn from the Cambridge Neuropsychological Testing Automated Battery (CANTAB) and other established paradigms. Alongside the cognitive testing battery we administered benchmark and parent-report assessments of cognition and behavior. Individuals with DS (n=74, ages 7-38 years) and mental age (MA) matched controls (n=50, ages 3-8 years) were tested across 3 sites. A subsample of these groups were used for between-group comparisons, including 55 individuals with DS and 36 mental age matched controls. The ACTB allows for low floor performance levels and participant loss. Floor effects were greater in younger children. Individuals with DS were impaired on a number ACTB tests in comparison to a MA-matched sample, with some areas of spared ability, particularly on tests requiring extensive motor coordination. Battery measures correlated with parent report of behavior and development. The ACTB provided consistent results across contexts, including home vs. lab visits, cross-site, and among individuals with a wide range of socio-economic backgrounds and differences in ethnicity. The ACTB will be useful in a range of outcome studies, including clinical trials and the identification of important genetic components of cognitive disability.

AB - Neurocognitive assessment in individuals with intellectual disabilities requires a well-validated test battery. To meet this need, the Arizona Cognitive Test Battery (ACTB) has been developed specifically to assess the cognitive phenotype in Down syndrome (DS). The ACTB includes neuropsychological assessments chosen to 1) assess a range of skills, 2) be non-verbal so as to not confound the neuropsychological assessment with language demands, 3) have distributional properties appropriate for research studies to identify genetic modifiers of variation, 4) show sensitivity to within and between sample differences, 5) have specific correlates with brain function, and 6) be applicable to a wide age range and across contexts. The ACTB includes tests of general cognitive ability and prefrontal, hippocampal and cerebellar function. These tasks were drawn from the Cambridge Neuropsychological Testing Automated Battery (CANTAB) and other established paradigms. Alongside the cognitive testing battery we administered benchmark and parent-report assessments of cognition and behavior. Individuals with DS (n=74, ages 7-38 years) and mental age (MA) matched controls (n=50, ages 3-8 years) were tested across 3 sites. A subsample of these groups were used for between-group comparisons, including 55 individuals with DS and 36 mental age matched controls. The ACTB allows for low floor performance levels and participant loss. Floor effects were greater in younger children. Individuals with DS were impaired on a number ACTB tests in comparison to a MA-matched sample, with some areas of spared ability, particularly on tests requiring extensive motor coordination. Battery measures correlated with parent report of behavior and development. The ACTB provided consistent results across contexts, including home vs. lab visits, cross-site, and among individuals with a wide range of socio-economic backgrounds and differences in ethnicity. The ACTB will be useful in a range of outcome studies, including clinical trials and the identification of important genetic components of cognitive disability.

KW - Assessment

KW - Clinical trials

KW - Down syndrome

KW - Genetics

KW - Intellectual disabilities

KW - Neuropsychology

UR - http://www.scopus.com/inward/record.url?scp=77955276385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955276385&partnerID=8YFLogxK

U2 - 10.1007/s11689-010-9054-3

DO - 10.1007/s11689-010-9054-3

M3 - Article

AN - SCOPUS:77955276385

VL - 2

SP - 149

EP - 164

JO - Journal of Neurodevelopmental Disorders

JF - Journal of Neurodevelopmental Disorders

SN - 1866-1947

IS - 3

ER -